SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID)

PHASE2RecruitingINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

June 16, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Post-COVID / Long-COVID

Interventions

DRUG

Placebo

A single dose of placebo (saline) indistinguishable from the active drug in appearance

BIOLOGICAL

Sipavibart

A single intramuscular dose of Sipavibart, 300 mg

Trial Locations (1)

RECRUITING

Nova Southeastern University, Fort Lauderdale

All Listed Sponsors

collaborator

Florida Department of Health

OTHER_GOV

lead

Nancy Klimas

OTHER

NCT07021794 - SARS-CoV-2 Specific Monoclonal Antibody for Post-COVID-19 Conditions (Long COVID) | Biotech Hunter | Biotech Hunter